DK3446706T3 - [6r]-mthf-fler-bolus-indgivelse i 5-fluoruracilbaseret kemoterapi - Google Patents

[6r]-mthf-fler-bolus-indgivelse i 5-fluoruracilbaseret kemoterapi Download PDF

Info

Publication number
DK3446706T3
DK3446706T3 DK18150457.2T DK18150457T DK3446706T3 DK 3446706 T3 DK3446706 T3 DK 3446706T3 DK 18150457 T DK18150457 T DK 18150457T DK 3446706 T3 DK3446706 T3 DK 3446706T3
Authority
DK
Denmark
Prior art keywords
mthf
fluoruracil
bolus administration
based chemotherapy
chemotherapy
Prior art date
Application number
DK18150457.2T
Other languages
English (en)
Inventor
Per Lennart Lindberg
Gunnel Elisabet Sundén
Bengt Gustavsson
Anders Vedin
Original Assignee
Isofol Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isofol Medical Ab filed Critical Isofol Medical Ab
Application granted granted Critical
Publication of DK3446706T3 publication Critical patent/DK3446706T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
DK18150457.2T 2017-08-24 2018-01-05 [6r]-mthf-fler-bolus-indgivelse i 5-fluoruracilbaseret kemoterapi DK3446706T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17187682.4A EP3446703A1 (en) 2017-08-24 2017-08-24 6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy

Publications (1)

Publication Number Publication Date
DK3446706T3 true DK3446706T3 (da) 2021-09-13

Family

ID=59702572

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18150457.2T DK3446706T3 (da) 2017-08-24 2018-01-05 [6r]-mthf-fler-bolus-indgivelse i 5-fluoruracilbaseret kemoterapi

Country Status (19)

Country Link
US (2) US10328079B2 (da)
EP (4) EP3446703A1 (da)
JP (3) JP2020531492A (da)
KR (1) KR102227451B1 (da)
CN (1) CN110214023A (da)
AU (1) AU2018319671A1 (da)
BR (1) BR112020003604A2 (da)
CA (2) CA3073608C (da)
DK (1) DK3446706T3 (da)
ES (1) ES2889573T3 (da)
HU (1) HUE056275T2 (da)
IL (1) IL272876B (da)
MX (1) MX2020002075A (da)
PL (1) PL3446706T3 (da)
PT (1) PT3446706T (da)
RU (1) RU2762596C2 (da)
SG (2) SG11202001371YA (da)
TW (1) TWI772354B (da)
WO (1) WO2019037899A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019016668A2 (pt) 2017-02-14 2020-04-07 Isofol Medical Ab métodos para aumentar a concentração de plasma de durd e para inibir timidilato-sintase (ts) em um indivíduo humano.
WO2023046307A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer
WO2023046305A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer
WO2023046304A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376658A (en) * 1990-05-11 1994-12-27 University Of Southern California 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN1942189A (zh) * 2004-04-02 2007-04-04 阿德文特克斯药物有限公司 5,10-亚甲基四氢叶酸在癌症治疗中的用途
CA2561952A1 (en) * 2004-04-02 2005-10-20 Adventrx Pharmaceuticals, Inc. Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
AU2006320388A1 (en) * 2005-12-02 2007-06-07 Adventrx Pharmaceuticals, Inc. Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
WO2008109349A1 (en) 2007-03-06 2008-09-12 Adventrx Pharmaceuticals, Inc. Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
EP2617421A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
EP3305318A1 (en) 2016-10-05 2018-04-11 Isofol Medical AB [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy

Also Published As

Publication number Publication date
RU2020109122A3 (da) 2021-09-24
JP6734308B2 (ja) 2020-08-05
HUE056275T2 (hu) 2022-02-28
EP3854399A1 (en) 2021-07-28
ES2889573T3 (es) 2022-01-12
CA3073608A1 (en) 2019-02-28
WO2019037899A1 (en) 2019-02-28
JP2020531492A (ja) 2020-11-05
KR102227451B1 (ko) 2021-03-12
MX2020002075A (es) 2020-08-13
PT3446706T (pt) 2021-09-15
JP2019038796A (ja) 2019-03-14
JP2020169208A (ja) 2020-10-15
AU2018319671A1 (en) 2020-03-05
EP3446703A1 (en) 2019-02-27
EP3672624A1 (en) 2020-07-01
IL272876A (en) 2020-04-30
SG11202001371YA (en) 2020-03-30
EP3446706A1 (en) 2019-02-27
RU2020109122A (ru) 2021-09-24
TW201912158A (zh) 2019-04-01
BR112020003604A2 (pt) 2020-09-01
CN110214023A (zh) 2019-09-06
CA2991361A1 (en) 2019-02-24
US10328079B2 (en) 2019-06-25
US20190060315A1 (en) 2019-02-28
KR20190022269A (ko) 2019-03-06
PL3446706T3 (pl) 2021-11-08
CA3073608C (en) 2022-02-01
RU2762596C2 (ru) 2021-12-21
US20190212341A1 (en) 2019-07-11
SG10201800203SA (en) 2019-03-28
IL272876B (en) 2021-12-01
TWI772354B (zh) 2022-08-01
EP3446706B1 (en) 2021-06-02

Similar Documents

Publication Publication Date Title
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
EP3613247A4 (en) COMMON GROUP PDCCH DESIGN IN NO
BR112017015514A2 (pt) derivados policíclicos ativos com substituintes contendo enxofre ativos em termos pesticidas
DK3188724T3 (da) Liposom-indkapslet affinitetsmedikament
DK3663292T3 (da) Diphenylmethan-derivat i krystallinsk form
GB2559719B (en) Maintaining privacy in location-based operations
BR112017028600A2 (pt) derivados policíclicos ativos com substituintes contendo enxofre ativos em termos pesticidas
DK3380146T3 (da) Medikamentadministrationsanordning
DK3325051T3 (da) Variabel enkeltdosisinjektor
DK3380139T3 (da) Medikamentadministrationsanordning
DK3204085T3 (da) Hus og lægemiddeladministrationsanordning hermed
DK3446706T3 (da) [6r]-mthf-fler-bolus-indgivelse i 5-fluoruracilbaseret kemoterapi
DK3275452T3 (da) Farmaceutisk sammensætning med silibinin
DK3265057T3 (da) Topisk formulering
DK3337353T3 (da) Stol
DK3226905T3 (da) Hyaluronan-konjugater med farmaceutisk aktive substanser, fremgangsmåder og sammensætninger
DK3349825T3 (da) Lægemiddeladministrationsanordning
DK3253749T3 (da) Forbindelser med antitumoraktivitet
DK3349827T3 (da) Lægemiddeladministrationsanordning
FR3032870B1 (fr) Structure de mobilier repliable, en particulier de mobilier d'enseignement
FR3025079B1 (fr) Mobilier multi-configuration
DK3446705T3 (da) [6r]-mthf et effektivt folat-alternativ i 5-fluoruracilbaseret kemoterapi
ES1135937Y (es) Estanteria
DK3434147T3 (da) Stol